Recognition Of Upfront & Milestone Payments was Entrada Therapeutics’s largest product and service line in fiscal 2025, bringing in $20.30M of $25.50M (80%).
| Product and Service | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Deferred Revenue At Inception | $103.70M | $123.50M | — |
| Recognition Of Upfront & Milestone Payments | $7.80M | $70.50M | $20.30M |
| Cost Reimbursements | $17.50M | $15.80M | $5.20M |
| Total | $129.00M | $209.80M | $25.50M |
Entrada Therapeutics brought in $25.50M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. Entrada Therapeutics regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $209.80M. Recognition Of Upfront & Milestone Payments was the largest at $20.30M (79.6%), ahead of Cost Reimbursements at $5.20M (20.4%).
Compared with fiscal 2024, Cost Reimbursements fell 67.1% to $5.20M and Recognition Of Upfront & Milestone Payments fell 71.2% to $20.30M.
Entrada Therapeutics stopped reporting Deferred Revenue At Inception as a separate line after fiscal 2024, when it brought in $123.50M.
Entrada Therapeutics (TRDA) reports its revenue by product and service. In fiscal 2025, Recognition Of Upfront & Milestone Payments was its largest product and service line, bringing in $20.30M (79.6% of the total), followed by Cost Reimbursements at $5.20M (20.4%).
Recognition Of Upfront & Milestone Payments was Entrada Therapeutics' largest product and service line in fiscal 2025, bringing in $20.30M, or 79.6% of the $25.50M total across its two product and service lines.
Every figure comes from Entrada Therapeutics' annual financial filings, as reported. Each line keeps the name Entrada Therapeutics gives it, and years follow its fiscal calendar.
Entrada Therapeutics' revenue by product and service goes back to fiscal 2023, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.